Charles Larkin
Papers
2
Total Citations
192
H-Index
2
About
Charles Larkin is a pioneering researcher in regenerative medicine, with a primary focus on cell-based therapies for Duchenne muscular dystrophy (DMD). His landmark contributions center on myoblast transfer therapy (MTT), an experimental approach aimed at restoring muscle function in DMD patients by injecting healthy donor muscle cells. In his most-cited work (1992, 106 citations), Larkin demonstrated the feasibility and safety of injecting five billion normal myoblasts into 21 DMD boys, targeting lower-limb strength in a Phase II trial. He extended this work in a 1993 study (86 citations), treating 32 boys—half nonambulatory—with 48 injections, further establishing MTT’s experimental potential. These studies, though early-stage, laid critical groundwork for cell transplantation as a DMD treatment, highlighting both promise and challenges. Larkin’s research has been instrumental in advancing the field of muscular dystrophy therapy, influencing subsequent gene and cell-based approaches. His work remains a touchstone for researchers exploring regenerative strategies, with his trials representing some of the first systematic attempts to translate cell therapy from bench to bedside for a devastating neuromuscular disease.
Research Focus
Key Achievements
Top Papers
- 1
- 2